Samantha Paoletti

⏰ Reminder to all startups in #medtech, #diagnostics, #pharma, and #labsystems! Don't let this opportunity slip away. Apply now for the Helbling Technik Venture Challenge, in partnership with Venturelab. 💡 This is your chance to win a consulting package valued at CHF 25,000 for due diligence or product development. 👇 Apply before the 21st of April! #WomenAndBeyondInMedteCH #SwissStartups #Helbling #Medtech #Diagnostics #LabSystems

3

📢 Pentixapharm AG Acquires Target Discovery Business of Glycotope GmbH, effective July 1st.  This strategic acquisition of the Berlin-based biotech company marks a significant milestone in their mission to develop novel targeted radiopharmaceuticals against a broad range of malignancies. 🌟 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻: • 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: The deal includes a portfolio of 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 against multiple oncology targets, 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀, cell banks, a 𝘁𝘂𝗺𝗼𝗿 𝘁𝗮𝗿𝗴𝗲𝘁 𝗱𝗮𝘁𝗮𝗯𝗮𝘀𝗲, and essential equipment.    • 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗜𝗻𝘁𝗲𝗹𝗹𝗲𝗰𝘁𝘂𝗮𝗹 𝗣𝗿𝗼𝗽𝗲𝗿𝘁𝘆: This acquisition broadens the 𝗜𝗣 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 beyond the CXCR4 receptor, 𝗱𝗼𝘂𝗯𝗹𝗶𝗻𝗴 the 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and expanding business and clinical opportunities.    • 𝗘𝘅𝗽𝗲𝗿𝘁 𝗧𝗲𝗮𝗺: Pentixapharm welcomes an 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝘁𝗲𝗮𝗺 𝗼𝗳 𝟰𝟬 seasoned executives, R&D specialists, and administrators from Glycotope.    • 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻: Patrik Kehler, former CSO of Glycotope, will join as Pentixapharm's 𝗖𝗦𝗢, and Henner Kollenberg, former CEO of Glycotope, will become the 𝗖𝗵𝗶𝗲𝗳 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗢𝗳𝗳𝗶𝗰𝗲𝗿.    💬 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗣𝗲𝗻𝘁𝗶𝘅𝗮𝗽𝗵𝗮𝗿𝗺'𝘀 𝗟𝗲𝗮𝗱𝗲𝗿𝘀: “Glycotope’s pipeline comprises 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 that can be 𝘂𝘀𝗲𝗱 𝗶𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲𝗹𝘆 for 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 as next generation radiopharmaceuticals,” said Dr. Hakim Bouterfa, CEO of Pentixapharm AG. “We look forward to 𝗺𝗮𝘅𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝘆𝗻𝗲𝗿𝗴𝘆 of Pentixapharm’s know-how and Glycotope’s target discovery for the 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 in both diagnostics and therapeutic applications.” “The transaction 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝘀 our 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and administrative capacities, facilitating a 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 to the 𝗙𝗿𝗮𝗻𝗸𝗳𝘂𝗿𝘁 𝗦𝘁𝗼𝗰𝗸 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲,” noted 𝗗𝗿. 𝗔𝗻𝗱𝗿𝗲𝗮𝘀 𝗘𝗰𝗸𝗲𝗿𝘁, Chairman of the Supervisory Board of both Pentixapharm and Eckert & Ziegler SE. This acquisition positions Pentixapharm to develop 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 by leveraging Glycotope’s 𝘂𝗻𝗶𝗾𝘂𝗲 𝗚𝗹𝘆𝗰𝗼𝗧𝗮𝗿𝗴𝗲𝘁𝘀—tumor-associated 𝗰𝗮𝗿𝗯𝗼𝗵𝘆𝗱𝗿𝗮𝘁𝗲 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲𝘀 with 𝘀𝘂𝗽𝗲𝗿𝗶𝗼𝗿 𝘁𝘂𝗺𝗼𝗿-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝗶𝘁𝘆. These advancements have the potential to close the treatment gap for many solid tumors, enhancing both diagnostic and therapeutic applications. 🔗 Learn More: https://lnkd.in/eCXh35Nw #NuclearMedicine #Radiopharmaceuticals #Acquisition #PrecisionMedicine  

106

Join our poster session at BiotechX next week in Basel and witness how we use our FAIRData-Omics tool to generate networks that inform scientists on the nature of mechanistic relationships between genes, pathways and diseases by indicating ‘positive’ and ‘negative’ correlations. #BiotechX #FAIR #Omics #KMAP

2

From problematic business models to quality issues and low incentives for peer review, scientific publishing faces many challenges. So how can we improve transparency around peer review and sharing scientific research? At the recent BlockSplit event, our co-founder Philipp Koellinger shared how DeSci Nodes can contribute to accelerating scientific progress. If you want to see how our tools work for yourself, get in touch to set up a meeting: https://bit.ly/Try-DeSci #ScientificResearch #ScientificPublishing #PeerReview

34

3 Kommentare

It was very inspiring to have Matthias Steger PhD, MBA, CEO of Endogena Therapeutics, Inc. speaking at our recent conference in Montreux on ¨Endogena Therapeutics – a novel drug discovery & development paradigm¨. Mats described how starting in 2016 he built a unique phenotypic drug discovery platform from scratch, focused on using AI and machine learning to find novel small molecules that restore stem cell function. Over 7 years later, Endogena now has two clinical programs in opthalmology and Mats argues that a phenotypic approach can deliver higher translational success. Agents can also offer wider applicability than therapies targeting specific genetic deficits. Mats faced a lot of scepticism and had to address every proof point sequentially. Initially peopole did not believe that retinal stem cells were present, then that they could be activated, and then that they would migrate to where they were needed. Careful diligent experiments dismantled each of the objections in turn, gradually unlocking further funding and partnering interest. All of this has resulted in groundbreaking publications. It was very moving to hear how Mats was motivated on his journey by a friend facing blindness from retinitis pigmentosa. We wish Mats every success in this amazing journey. https://endogena.com/ Please look out for the ¨save the date¨ announcement for our 2025 conference! #swisshlg #biopharma #dealmaking #innovation #networking #endogena

42

5 Kommentare

🎥 Check out this short video of @𝗘𝘂𝗴𝗲𝗻𝗶𝗼 𝗙𝗮𝘃𝗮 from @DZNE sharing some great practical insights into recent developments in #neuroscience and early drug discovery. 👨‍🔬 "Drug discovery starts with understanding diseases and their mechanisms, identifying critical targets, and leveraging innovative technologies. Despite advances, challenges remain, such as the unclear mechanisms in diseases like Alzheimer's, highlighting the need for continuous evolution." ✨

1

𝑵𝙚𝒘 𝑾𝙚𝒆𝙠 - 𝙉𝒆𝙬 𝙈𝒆𝙢𝒃𝙚𝒓! Welcome NEC Bio Therapeutics GmbH on the BioRN planet 🌍 NEC Bio Therapeutics is a clinical-stage biotechnology company developing artificial intelligence empowered personalized immunotherapies for cancer patients which target personalized neoantigens. The focus of NEC Bio Therapeutics is on the clinical development of personalised cancer vaccines. The main product is NEVAX-NEO1, a clinical-stage personalised oral tumour vaccine consisting of live, strongly attenuated bacterium carrying a plasmid DNA encoding for a polyepitope peptide consisting of tumour-specific neoantigens. The neoantigens are identified by Next Generation Sequencing (NGS) of patient-specific tumour biopsies and subsequent identification and ranking of potential tumour-specific neo-epitopes using the proprietary NEC Immune Profiler software. NECVAX-NEO1 is being developed in a series of clinical trials in various indications of solid tumours, covering the spectrum of different stages from early treatment in the neoadjuvant setting up to treatment of metastatic patients, including standard of care immune checkpoint inhibitor therapy. NEVAX-NEO1 is based on a clinically validated plug&play platform technology which is self-adjuvanted through the bacterial carrier. The turnaround time is short due to the straight-forward small scale manufacturing process, enabling treatment of patients with metastatic disease. The technology enables targeting of a large number of neoantigens of any size and is applicable to personalised as well as shared neoantigen-targeting approaches. If you want to learn more get in contact with Heinz Lubenau. Looking forward to your active participation in our network!

20

The team from Chondrometrics GmbH and the Research Program for Imaging at Paracelsus Medizinische Privatuniversität in #Austria is excited to meet you at the OARSI - Osteoarthritis Research Society International Conference 2024 in #Vienna. It is represented by Susanne Maschek (Chief of Human Resources and Quality Control), Wolfgang Wirth (Chief Technical Officer and Chief of Quality Control), Clemens Heistracher (PhD Student), and Felix Eckstein (CEO & CMO). Please join us for Oral Presentation No. 20 at the Imaging Session on Friday, April 19th, at 9:45 a.m., and for a review presentation at the China-Germany-Night on the same day at 6:45 p.m. Also feel free do drop by our posters No. 84 and 90 (#AdvancedBioinformatics), No. 204 (#Biomechanics & #Gait), and No. 491, 492, and 493 (#Imaging) displayed during the two #PosterSessions. We look forward to engaging in interesting scientific discussions or simply having a friendly chat. Enjoy #Vienna! #Chondrometrics, #ParacelsusMedicalUniversity, #OARSIConference, #WorldCongress, #Osteoarthritis, #Research, #ClinicalTrial, #Reading, #Cartilage, #DMOAD, #Segmentation, #T2, #Diabetes, #SensitivityToChange, #MagneticFieldStrength, #JSW, #SexualDimorphism

37

5 Kommentare

🔬 🧫 🧬 Don’t miss out on an exclusive roundtable discussion on "Developing Therapies that Target Multiple Immune Pathways" at the Antibody Therapeutics Xchange - Brussels! 🗓 18 Nov 2024 | 09:05 - 10:05 CET 📍 Bi/Multispecifics Track Key topics include: ✅ Optimal design for a multispecific TCE - what have we learned, and what’s next? ✅ Improving tumor selectivity - do we need new combinations of TAAs? ✅ Checkpoint inhibition - address it in the same molecule or separately? 🔑 Led by Leonard Wossnig, CTO at LabGenius an expert in AI, quantum machine learning, and computational drug design. 💡 Secure your FREE spot! https://lnkd.in/eQWzNrAH Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyTherapeutics #BiSpecifics #Multispecifics #CancerResearch #Immunotherapy #AIInHealthcare #LabGenius #DrugDiscovery #PrecisionMedicine #ImmunePathways #TCellEngagers #CheckpointInhibition #Oncology #Pharma #Biotech #HealthcareInnovation #Xchange2024 #PharmaTech #Biopharma #Brussels2024 #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

47

[NEW Podcast] In this episode we talked with Dr. Stephan Hamperl from Epigenetics Research at Helmholtz Munich about his work on how conflicts between transcription, replication, and R-loop formation influence genome stability in human cells. 🎧 https://bit.ly/3XGHx07 #epigenetics #podcast

8

🔗🧬 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗔𝗰𝗮𝗱𝗲𝗺𝗶𝗰 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆: 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝘄𝗶𝘁𝗵 𝗣𝘀𝗲𝘂𝗱𝗼𝘃𝗶𝗿𝘂𝘀 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀 At Microbe Investigations Switzerland (MIS), we're dedicated to advancing how academic research and industry collaborate through cutting-edge pseudovirus platforms. 🌍🔬 🎓🏭 Our latest initiatives aim to foster seamless transitions from groundbreaking research to practical applications, enhancing both public health defenses and industrial innovation. By integrating academic discoveries with industry needs, we provide tailored testing solutions that pave the way for safer, more effective products. 📖 Read Our Latest Article: Dive deeper into our initiatives and discover the potential for collaboration on pseudovirus platforms. https://lnkd.in/gjnyE_5Y 🌟 Whether you're in academia looking to bring your research into real-world applications, or an industry professional seeking rigorous, evidence-based testing services, MIS is your partner in innovation. 👉 Learn more about how we're supporting these initiatives and explore opportunities for collaboration: Visit our website #ResearchAndDevelopment #IndustryCollaboration #VirologyLab #PseudovirusPlatforms #PublicHealth #Innovation #MIS

1